| Name | Title | Contact Details |
|---|
ABC Medical Management is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BridgeHealth connects people with the nation`s best surgical care for a better experience, better outcomes, and better value. We offer a value-based approach to surgical care for self-insured plan sponsors and their members, saving them an average of 30% to 50% on procedures compared with PPO rates. BridgeHealth`s nationwide Centers of Excellence focus on quality outcomes and provide pre-negotiated bundled case rates for a broad scope of surgical procedures, including musculoskeletal, neurological, general surgery, cardiac, bariatric, and women`s health. BridgeHealth contracts with hospital providers who rank in the top quartile for their clinical specialty, based on outcomes and other objective measures, as well as top-rated ambulatory surgery centers. Plan members gain access to some of the best providers in the country, with little to no out-of-pocket expense. They receive concierge-level service, with a personal care coordinator to assist them every step of the way. They also have access to unbiased decision support tools to help them with second opinions, alternative treatments, and provider selection. Plan sponsors recognize significant cost savings, increased engagement, and increased productivity, along with recruitment and retention advantages, by offering a benefit that improves outcomes and reduces costs.
World Medical Solutions is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Occupational Health and Hygiene Corporation of America is a Lebanon, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.